Global Messenger RNA Vaccines and Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Messenger RNA Vaccines and Therapeutics market size was valued at USD 10080 million in 2022 and is forecast to a readjusted size of USD 22370 million by 2029 with a CAGR of 12.1% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
An mRNA vaccine is a vaccine that uses a molecular copy of messenger RNA to generate an immune response. [1] Such vaccines deliver antigen-coding mRNA molecules into immune cells, which use the designed mRNA as a template to build foreign proteins normally produced by pathogens such as viruses or cancer cells. These protein molecules stimulate an adaptive immune response, teaching the body to recognize and destroy the corresponding pathogen or cancer cell. mRNA is composed of RNA encapsulated in lipid nanoparticles, which protect the RNA strand and facilitate its uptake into cells. Reactogenicity, the propensity of the vaccine to produce adverse reactions, was similar to that of traditional non-RNA vaccines. People prone to autoimmune reactions may experience adverse reactions to messenger RNA vaccines. Compared with traditional vaccines, mRNA vaccines have the advantages of being easy to design, fast in production, low in cost, capable of inducing cellular and humoral immunity, and not interacting with genomic DNA.
This report is a detailed and comprehensive analysis for global Messenger RNA Vaccines and Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Messenger RNA Vaccines and Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
Global Messenger RNA Vaccines and Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Messenger RNA Vaccines and Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Messenger RNA Vaccines and Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Messenger RNA Vaccines and Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Messenger RNA Vaccines and Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BioNTech, Moderna, CureVac, Pfizer and Glaxo Smith Kline's, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Messenger RNA Vaccines and Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Messenger RNA Vaccines and Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Messenger RNA Vaccines and Therapeutics, with revenue, gross margin and global market share of Messenger RNA Vaccines and Therapeutics from 2018 to 2023.
Chapter 3, the Messenger RNA Vaccines and Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Messenger RNA Vaccines and Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Messenger RNA Vaccines and Therapeutics.
Chapter 13, to describe Messenger RNA Vaccines and Therapeutics research findings and conclusion.
An mRNA vaccine is a vaccine that uses a molecular copy of messenger RNA to generate an immune response. [1] Such vaccines deliver antigen-coding mRNA molecules into immune cells, which use the designed mRNA as a template to build foreign proteins normally produced by pathogens such as viruses or cancer cells. These protein molecules stimulate an adaptive immune response, teaching the body to recognize and destroy the corresponding pathogen or cancer cell. mRNA is composed of RNA encapsulated in lipid nanoparticles, which protect the RNA strand and facilitate its uptake into cells. Reactogenicity, the propensity of the vaccine to produce adverse reactions, was similar to that of traditional non-RNA vaccines. People prone to autoimmune reactions may experience adverse reactions to messenger RNA vaccines. Compared with traditional vaccines, mRNA vaccines have the advantages of being easy to design, fast in production, low in cost, capable of inducing cellular and humoral immunity, and not interacting with genomic DNA.
This report is a detailed and comprehensive analysis for global Messenger RNA Vaccines and Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Messenger RNA Vaccines and Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
Global Messenger RNA Vaccines and Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Messenger RNA Vaccines and Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Messenger RNA Vaccines and Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Messenger RNA Vaccines and Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Messenger RNA Vaccines and Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BioNTech, Moderna, CureVac, Pfizer and Glaxo Smith Kline's, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Messenger RNA Vaccines and Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Self-amplifying
- Conventional Non-amplifying
- Cancer
- Infectious Diseases
- Autoimmune Diseases
- Others
- BioNTech
- Moderna
- CureVac
- Pfizer
- Glaxo Smith Kline's
- Daiichi Sankyo Company
- Intellia Therapeutics
- Arcturus Therapeutics
- Emmy Vaccine
- CSPC
- CanSino
- Fosun Pharma
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Messenger RNA Vaccines and Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Messenger RNA Vaccines and Therapeutics, with revenue, gross margin and global market share of Messenger RNA Vaccines and Therapeutics from 2018 to 2023.
Chapter 3, the Messenger RNA Vaccines and Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Messenger RNA Vaccines and Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Messenger RNA Vaccines and Therapeutics.
Chapter 13, to describe Messenger RNA Vaccines and Therapeutics research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Messenger RNA Vaccines and Therapeutics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Messenger RNA Vaccines and Therapeutics by Type
1.3.1 Overview: Global Messenger RNA Vaccines and Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type in 2022
1.3.3 Self-amplifying
1.3.4 Conventional Non-amplifying
1.4 Global Messenger RNA Vaccines and Therapeutics Market by Application
1.4.1 Overview: Global Messenger RNA Vaccines and Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Cancer
1.4.3 Infectious Diseases
1.4.4 Autoimmune Diseases
1.4.5 Others
1.5 Global Messenger RNA Vaccines and Therapeutics Market Size & Forecast
1.6 Global Messenger RNA Vaccines and Therapeutics Market Size and Forecast by Region
1.6.1 Global Messenger RNA Vaccines and Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Messenger RNA Vaccines and Therapeutics Market Size by Region, (2018-2029)
1.6.3 North America Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
1.6.4 Europe Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
1.6.6 South America Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 BioNTech
2.1.1 BioNTech Details
2.1.2 BioNTech Major Business
2.1.3 BioNTech Messenger RNA Vaccines and Therapeutics Product and Solutions
2.1.4 BioNTech Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 BioNTech Recent Developments and Future Plans
2.2 Moderna
2.2.1 Moderna Details
2.2.2 Moderna Major Business
2.2.3 Moderna Messenger RNA Vaccines and Therapeutics Product and Solutions
2.2.4 Moderna Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Moderna Recent Developments and Future Plans
2.3 CureVac
2.3.1 CureVac Details
2.3.2 CureVac Major Business
2.3.3 CureVac Messenger RNA Vaccines and Therapeutics Product and Solutions
2.3.4 CureVac Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 CureVac Recent Developments and Future Plans
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Messenger RNA Vaccines and Therapeutics Product and Solutions
2.4.4 Pfizer Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Pfizer Recent Developments and Future Plans
2.5 Glaxo Smith Kline's
2.5.1 Glaxo Smith Kline's Details
2.5.2 Glaxo Smith Kline's Major Business
2.5.3 Glaxo Smith Kline's Messenger RNA Vaccines and Therapeutics Product and Solutions
2.5.4 Glaxo Smith Kline's Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Glaxo Smith Kline's Recent Developments and Future Plans
2.6 Daiichi Sankyo Company
2.6.1 Daiichi Sankyo Company Details
2.6.2 Daiichi Sankyo Company Major Business
2.6.3 Daiichi Sankyo Company Messenger RNA Vaccines and Therapeutics Product and Solutions
2.6.4 Daiichi Sankyo Company Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Daiichi Sankyo Company Recent Developments and Future Plans
2.7 Intellia Therapeutics
2.7.1 Intellia Therapeutics Details
2.7.2 Intellia Therapeutics Major Business
2.7.3 Intellia Therapeutics Messenger RNA Vaccines and Therapeutics Product and Solutions
2.7.4 Intellia Therapeutics Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Intellia Therapeutics Recent Developments and Future Plans
2.8 Arcturus Therapeutics
2.8.1 Arcturus Therapeutics Details
2.8.2 Arcturus Therapeutics Major Business
2.8.3 Arcturus Therapeutics Messenger RNA Vaccines and Therapeutics Product and Solutions
2.8.4 Arcturus Therapeutics Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Arcturus Therapeutics Recent Developments and Future Plans
2.9 Emmy Vaccine
2.9.1 Emmy Vaccine Details
2.9.2 Emmy Vaccine Major Business
2.9.3 Emmy Vaccine Messenger RNA Vaccines and Therapeutics Product and Solutions
2.9.4 Emmy Vaccine Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Emmy Vaccine Recent Developments and Future Plans
2.10 CSPC
2.10.1 CSPC Details
2.10.2 CSPC Major Business
2.10.3 CSPC Messenger RNA Vaccines and Therapeutics Product and Solutions
2.10.4 CSPC Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 CSPC Recent Developments and Future Plans
2.11 CanSino
2.11.1 CanSino Details
2.11.2 CanSino Major Business
2.11.3 CanSino Messenger RNA Vaccines and Therapeutics Product and Solutions
2.11.4 CanSino Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 CanSino Recent Developments and Future Plans
2.12 Fosun Pharma
2.12.1 Fosun Pharma Details
2.12.2 Fosun Pharma Major Business
2.12.3 Fosun Pharma Messenger RNA Vaccines and Therapeutics Product and Solutions
2.12.4 Fosun Pharma Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Fosun Pharma Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Messenger RNA Vaccines and Therapeutics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Messenger RNA Vaccines and Therapeutics by Company Revenue
3.2.2 Top 3 Messenger RNA Vaccines and Therapeutics Players Market Share in 2022
3.2.3 Top 6 Messenger RNA Vaccines and Therapeutics Players Market Share in 2022
3.3 Messenger RNA Vaccines and Therapeutics Market: Overall Company Footprint Analysis
3.3.1 Messenger RNA Vaccines and Therapeutics Market: Region Footprint
3.3.2 Messenger RNA Vaccines and Therapeutics Market: Company Product Type Footprint
3.3.3 Messenger RNA Vaccines and Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Messenger RNA Vaccines and Therapeutics Consumption Value and Market Share by Type (2018-2023)
4.2 Global Messenger RNA Vaccines and Therapeutics Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2023)
5.2 Global Messenger RNA Vaccines and Therapeutics Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
6.2 North America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
6.3 North America Messenger RNA Vaccines and Therapeutics Market Size by Country
6.3.1 North America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2029)
6.3.2 United States Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
6.3.3 Canada Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
6.3.4 Mexico Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
7.2 Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
7.3 Europe Messenger RNA Vaccines and Therapeutics Market Size by Country
7.3.1 Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2029)
7.3.2 Germany Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7.3.3 France Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7.3.5 Russia Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7.3.6 Italy Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Messenger RNA Vaccines and Therapeutics Market Size by Region
8.3.1 Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Region (2018-2029)
8.3.2 China Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.3 Japan Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.4 South Korea Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.5 India Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.7 Australia Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
9.2 South America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
9.3 South America Messenger RNA Vaccines and Therapeutics Market Size by Country
9.3.1 South America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2029)
9.3.2 Brazil Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
9.3.3 Argentina Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Messenger RNA Vaccines and Therapeutics Market Size by Country
10.3.1 Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2029)
10.3.2 Turkey Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
10.3.4 UAE Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Messenger RNA Vaccines and Therapeutics Market Drivers
11.2 Messenger RNA Vaccines and Therapeutics Market Restraints
11.3 Messenger RNA Vaccines and Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Messenger RNA Vaccines and Therapeutics Industry Chain
12.2 Messenger RNA Vaccines and Therapeutics Upstream Analysis
12.3 Messenger RNA Vaccines and Therapeutics Midstream Analysis
12.4 Messenger RNA Vaccines and Therapeutics Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Messenger RNA Vaccines and Therapeutics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Messenger RNA Vaccines and Therapeutics by Type
1.3.1 Overview: Global Messenger RNA Vaccines and Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type in 2022
1.3.3 Self-amplifying
1.3.4 Conventional Non-amplifying
1.4 Global Messenger RNA Vaccines and Therapeutics Market by Application
1.4.1 Overview: Global Messenger RNA Vaccines and Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Cancer
1.4.3 Infectious Diseases
1.4.4 Autoimmune Diseases
1.4.5 Others
1.5 Global Messenger RNA Vaccines and Therapeutics Market Size & Forecast
1.6 Global Messenger RNA Vaccines and Therapeutics Market Size and Forecast by Region
1.6.1 Global Messenger RNA Vaccines and Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Messenger RNA Vaccines and Therapeutics Market Size by Region, (2018-2029)
1.6.3 North America Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
1.6.4 Europe Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
1.6.6 South America Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 BioNTech
2.1.1 BioNTech Details
2.1.2 BioNTech Major Business
2.1.3 BioNTech Messenger RNA Vaccines and Therapeutics Product and Solutions
2.1.4 BioNTech Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 BioNTech Recent Developments and Future Plans
2.2 Moderna
2.2.1 Moderna Details
2.2.2 Moderna Major Business
2.2.3 Moderna Messenger RNA Vaccines and Therapeutics Product and Solutions
2.2.4 Moderna Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Moderna Recent Developments and Future Plans
2.3 CureVac
2.3.1 CureVac Details
2.3.2 CureVac Major Business
2.3.3 CureVac Messenger RNA Vaccines and Therapeutics Product and Solutions
2.3.4 CureVac Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 CureVac Recent Developments and Future Plans
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Messenger RNA Vaccines and Therapeutics Product and Solutions
2.4.4 Pfizer Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Pfizer Recent Developments and Future Plans
2.5 Glaxo Smith Kline's
2.5.1 Glaxo Smith Kline's Details
2.5.2 Glaxo Smith Kline's Major Business
2.5.3 Glaxo Smith Kline's Messenger RNA Vaccines and Therapeutics Product and Solutions
2.5.4 Glaxo Smith Kline's Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Glaxo Smith Kline's Recent Developments and Future Plans
2.6 Daiichi Sankyo Company
2.6.1 Daiichi Sankyo Company Details
2.6.2 Daiichi Sankyo Company Major Business
2.6.3 Daiichi Sankyo Company Messenger RNA Vaccines and Therapeutics Product and Solutions
2.6.4 Daiichi Sankyo Company Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Daiichi Sankyo Company Recent Developments and Future Plans
2.7 Intellia Therapeutics
2.7.1 Intellia Therapeutics Details
2.7.2 Intellia Therapeutics Major Business
2.7.3 Intellia Therapeutics Messenger RNA Vaccines and Therapeutics Product and Solutions
2.7.4 Intellia Therapeutics Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Intellia Therapeutics Recent Developments and Future Plans
2.8 Arcturus Therapeutics
2.8.1 Arcturus Therapeutics Details
2.8.2 Arcturus Therapeutics Major Business
2.8.3 Arcturus Therapeutics Messenger RNA Vaccines and Therapeutics Product and Solutions
2.8.4 Arcturus Therapeutics Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Arcturus Therapeutics Recent Developments and Future Plans
2.9 Emmy Vaccine
2.9.1 Emmy Vaccine Details
2.9.2 Emmy Vaccine Major Business
2.9.3 Emmy Vaccine Messenger RNA Vaccines and Therapeutics Product and Solutions
2.9.4 Emmy Vaccine Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Emmy Vaccine Recent Developments and Future Plans
2.10 CSPC
2.10.1 CSPC Details
2.10.2 CSPC Major Business
2.10.3 CSPC Messenger RNA Vaccines and Therapeutics Product and Solutions
2.10.4 CSPC Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 CSPC Recent Developments and Future Plans
2.11 CanSino
2.11.1 CanSino Details
2.11.2 CanSino Major Business
2.11.3 CanSino Messenger RNA Vaccines and Therapeutics Product and Solutions
2.11.4 CanSino Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 CanSino Recent Developments and Future Plans
2.12 Fosun Pharma
2.12.1 Fosun Pharma Details
2.12.2 Fosun Pharma Major Business
2.12.3 Fosun Pharma Messenger RNA Vaccines and Therapeutics Product and Solutions
2.12.4 Fosun Pharma Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Fosun Pharma Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Messenger RNA Vaccines and Therapeutics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Messenger RNA Vaccines and Therapeutics by Company Revenue
3.2.2 Top 3 Messenger RNA Vaccines and Therapeutics Players Market Share in 2022
3.2.3 Top 6 Messenger RNA Vaccines and Therapeutics Players Market Share in 2022
3.3 Messenger RNA Vaccines and Therapeutics Market: Overall Company Footprint Analysis
3.3.1 Messenger RNA Vaccines and Therapeutics Market: Region Footprint
3.3.2 Messenger RNA Vaccines and Therapeutics Market: Company Product Type Footprint
3.3.3 Messenger RNA Vaccines and Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Messenger RNA Vaccines and Therapeutics Consumption Value and Market Share by Type (2018-2023)
4.2 Global Messenger RNA Vaccines and Therapeutics Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2023)
5.2 Global Messenger RNA Vaccines and Therapeutics Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
6.2 North America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
6.3 North America Messenger RNA Vaccines and Therapeutics Market Size by Country
6.3.1 North America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2029)
6.3.2 United States Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
6.3.3 Canada Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
6.3.4 Mexico Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
7.2 Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
7.3 Europe Messenger RNA Vaccines and Therapeutics Market Size by Country
7.3.1 Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2029)
7.3.2 Germany Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7.3.3 France Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7.3.5 Russia Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7.3.6 Italy Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Messenger RNA Vaccines and Therapeutics Market Size by Region
8.3.1 Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Region (2018-2029)
8.3.2 China Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.3 Japan Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.4 South Korea Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.5 India Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.7 Australia Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
9.2 South America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
9.3 South America Messenger RNA Vaccines and Therapeutics Market Size by Country
9.3.1 South America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2029)
9.3.2 Brazil Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
9.3.3 Argentina Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Messenger RNA Vaccines and Therapeutics Market Size by Country
10.3.1 Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2029)
10.3.2 Turkey Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
10.3.4 UAE Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Messenger RNA Vaccines and Therapeutics Market Drivers
11.2 Messenger RNA Vaccines and Therapeutics Market Restraints
11.3 Messenger RNA Vaccines and Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Messenger RNA Vaccines and Therapeutics Industry Chain
12.2 Messenger RNA Vaccines and Therapeutics Upstream Analysis
12.3 Messenger RNA Vaccines and Therapeutics Midstream Analysis
12.4 Messenger RNA Vaccines and Therapeutics Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 5. BioNTech Company Information, Head Office, and Major Competitors
Table 6. BioNTech Major Business
Table 7. BioNTech Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 8. BioNTech Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. BioNTech Recent Developments and Future Plans
Table 10. Moderna Company Information, Head Office, and Major Competitors
Table 11. Moderna Major Business
Table 12. Moderna Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 13. Moderna Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Moderna Recent Developments and Future Plans
Table 15. CureVac Company Information, Head Office, and Major Competitors
Table 16. CureVac Major Business
Table 17. CureVac Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 18. CureVac Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. CureVac Recent Developments and Future Plans
Table 20. Pfizer Company Information, Head Office, and Major Competitors
Table 21. Pfizer Major Business
Table 22. Pfizer Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 23. Pfizer Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Pfizer Recent Developments and Future Plans
Table 25. Glaxo Smith Kline's Company Information, Head Office, and Major Competitors
Table 26. Glaxo Smith Kline's Major Business
Table 27. Glaxo Smith Kline's Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 28. Glaxo Smith Kline's Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Glaxo Smith Kline's Recent Developments and Future Plans
Table 30. Daiichi Sankyo Company Company Information, Head Office, and Major Competitors
Table 31. Daiichi Sankyo Company Major Business
Table 32. Daiichi Sankyo Company Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 33. Daiichi Sankyo Company Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Daiichi Sankyo Company Recent Developments and Future Plans
Table 35. Intellia Therapeutics Company Information, Head Office, and Major Competitors
Table 36. Intellia Therapeutics Major Business
Table 37. Intellia Therapeutics Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 38. Intellia Therapeutics Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Intellia Therapeutics Recent Developments and Future Plans
Table 40. Arcturus Therapeutics Company Information, Head Office, and Major Competitors
Table 41. Arcturus Therapeutics Major Business
Table 42. Arcturus Therapeutics Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 43. Arcturus Therapeutics Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Arcturus Therapeutics Recent Developments and Future Plans
Table 45. Emmy Vaccine Company Information, Head Office, and Major Competitors
Table 46. Emmy Vaccine Major Business
Table 47. Emmy Vaccine Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 48. Emmy Vaccine Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Emmy Vaccine Recent Developments and Future Plans
Table 50. CSPC Company Information, Head Office, and Major Competitors
Table 51. CSPC Major Business
Table 52. CSPC Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 53. CSPC Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. CSPC Recent Developments and Future Plans
Table 55. CanSino Company Information, Head Office, and Major Competitors
Table 56. CanSino Major Business
Table 57. CanSino Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 58. CanSino Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. CanSino Recent Developments and Future Plans
Table 60. Fosun Pharma Company Information, Head Office, and Major Competitors
Table 61. Fosun Pharma Major Business
Table 62. Fosun Pharma Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 63. Fosun Pharma Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Fosun Pharma Recent Developments and Future Plans
Table 65. Global Messenger RNA Vaccines and Therapeutics Revenue (USD Million) by Players (2018-2023)
Table 66. Global Messenger RNA Vaccines and Therapeutics Revenue Share by Players (2018-2023)
Table 67. Breakdown of Messenger RNA Vaccines and Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 68. Market Position of Players in Messenger RNA Vaccines and Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 69. Head Office of Key Messenger RNA Vaccines and Therapeutics Players
Table 70. Messenger RNA Vaccines and Therapeutics Market: Company Product Type Footprint
Table 71. Messenger RNA Vaccines and Therapeutics Market: Company Product Application Footprint
Table 72. Messenger RNA Vaccines and Therapeutics New Market Entrants and Barriers to Market Entry
Table 73. Messenger RNA Vaccines and Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 74. Global Messenger RNA Vaccines and Therapeutics Consumption Value (USD Million) by Type (2018-2023)
Table 75. Global Messenger RNA Vaccines and Therapeutics Consumption Value Share by Type (2018-2023)
Table 76. Global Messenger RNA Vaccines and Therapeutics Consumption Value Forecast by Type (2024-2029)
Table 77. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2023)
Table 78. Global Messenger RNA Vaccines and Therapeutics Consumption Value Forecast by Application (2024-2029)
Table 79. North America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 80. North America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 81. North America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 82. North America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 83. North America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 84. North America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 85. Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 86. Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 87. Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 88. Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 89. Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 92. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 93. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 94. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 95. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 96. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 97. South America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 98. South America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 99. South America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 100. South America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 101. South America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 102. South America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 103. Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 104. Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 105. Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 106. Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 107. Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 108. Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 109. Messenger RNA Vaccines and Therapeutics Raw Material
Table 110. Key Suppliers of Messenger RNA Vaccines and Therapeutics Raw Materials
Table 1. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 5. BioNTech Company Information, Head Office, and Major Competitors
Table 6. BioNTech Major Business
Table 7. BioNTech Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 8. BioNTech Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. BioNTech Recent Developments and Future Plans
Table 10. Moderna Company Information, Head Office, and Major Competitors
Table 11. Moderna Major Business
Table 12. Moderna Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 13. Moderna Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Moderna Recent Developments and Future Plans
Table 15. CureVac Company Information, Head Office, and Major Competitors
Table 16. CureVac Major Business
Table 17. CureVac Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 18. CureVac Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. CureVac Recent Developments and Future Plans
Table 20. Pfizer Company Information, Head Office, and Major Competitors
Table 21. Pfizer Major Business
Table 22. Pfizer Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 23. Pfizer Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Pfizer Recent Developments and Future Plans
Table 25. Glaxo Smith Kline's Company Information, Head Office, and Major Competitors
Table 26. Glaxo Smith Kline's Major Business
Table 27. Glaxo Smith Kline's Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 28. Glaxo Smith Kline's Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Glaxo Smith Kline's Recent Developments and Future Plans
Table 30. Daiichi Sankyo Company Company Information, Head Office, and Major Competitors
Table 31. Daiichi Sankyo Company Major Business
Table 32. Daiichi Sankyo Company Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 33. Daiichi Sankyo Company Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Daiichi Sankyo Company Recent Developments and Future Plans
Table 35. Intellia Therapeutics Company Information, Head Office, and Major Competitors
Table 36. Intellia Therapeutics Major Business
Table 37. Intellia Therapeutics Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 38. Intellia Therapeutics Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Intellia Therapeutics Recent Developments and Future Plans
Table 40. Arcturus Therapeutics Company Information, Head Office, and Major Competitors
Table 41. Arcturus Therapeutics Major Business
Table 42. Arcturus Therapeutics Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 43. Arcturus Therapeutics Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Arcturus Therapeutics Recent Developments and Future Plans
Table 45. Emmy Vaccine Company Information, Head Office, and Major Competitors
Table 46. Emmy Vaccine Major Business
Table 47. Emmy Vaccine Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 48. Emmy Vaccine Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Emmy Vaccine Recent Developments and Future Plans
Table 50. CSPC Company Information, Head Office, and Major Competitors
Table 51. CSPC Major Business
Table 52. CSPC Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 53. CSPC Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. CSPC Recent Developments and Future Plans
Table 55. CanSino Company Information, Head Office, and Major Competitors
Table 56. CanSino Major Business
Table 57. CanSino Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 58. CanSino Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. CanSino Recent Developments and Future Plans
Table 60. Fosun Pharma Company Information, Head Office, and Major Competitors
Table 61. Fosun Pharma Major Business
Table 62. Fosun Pharma Messenger RNA Vaccines and Therapeutics Product and Solutions
Table 63. Fosun Pharma Messenger RNA Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Fosun Pharma Recent Developments and Future Plans
Table 65. Global Messenger RNA Vaccines and Therapeutics Revenue (USD Million) by Players (2018-2023)
Table 66. Global Messenger RNA Vaccines and Therapeutics Revenue Share by Players (2018-2023)
Table 67. Breakdown of Messenger RNA Vaccines and Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 68. Market Position of Players in Messenger RNA Vaccines and Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 69. Head Office of Key Messenger RNA Vaccines and Therapeutics Players
Table 70. Messenger RNA Vaccines and Therapeutics Market: Company Product Type Footprint
Table 71. Messenger RNA Vaccines and Therapeutics Market: Company Product Application Footprint
Table 72. Messenger RNA Vaccines and Therapeutics New Market Entrants and Barriers to Market Entry
Table 73. Messenger RNA Vaccines and Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 74. Global Messenger RNA Vaccines and Therapeutics Consumption Value (USD Million) by Type (2018-2023)
Table 75. Global Messenger RNA Vaccines and Therapeutics Consumption Value Share by Type (2018-2023)
Table 76. Global Messenger RNA Vaccines and Therapeutics Consumption Value Forecast by Type (2024-2029)
Table 77. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2023)
Table 78. Global Messenger RNA Vaccines and Therapeutics Consumption Value Forecast by Application (2024-2029)
Table 79. North America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 80. North America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 81. North America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 82. North America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 83. North America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 84. North America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 85. Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 86. Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 87. Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 88. Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 89. Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 92. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 93. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 94. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 95. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 96. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 97. South America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 98. South America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 99. South America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 100. South America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 101. South America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 102. South America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 103. Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 104. Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 105. Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 106. Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 107. Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 108. Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 109. Messenger RNA Vaccines and Therapeutics Raw Material
Table 110. Key Suppliers of Messenger RNA Vaccines and Therapeutics Raw Materials
LIST OF FIGURES
Figure 1. Messenger RNA Vaccines and Therapeutics Picture
Figure 2. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type in 2022
Figure 4. Self-amplifying
Figure 5. Conventional Non-amplifying
Figure 6. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application in 2022
Figure 8. Cancer Picture
Figure 9. Infectious Diseases Picture
Figure 10. Autoimmune Diseases Picture
Figure 11. Others Picture
Figure 12. Global Messenger RNA Vaccines and Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Messenger RNA Vaccines and Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Market Messenger RNA Vaccines and Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 15. Global Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 16. Global Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Region in 2022
Figure 17. North America Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. Europe Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. South America Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. Middle East and Africa Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. Global Messenger RNA Vaccines and Therapeutics Revenue Share by Players in 2022
Figure 23. Messenger RNA Vaccines and Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 24. Global Top 3 Players Messenger RNA Vaccines and Therapeutics Market Share in 2022
Figure 25. Global Top 6 Players Messenger RNA Vaccines and Therapeutics Market Share in 2022
Figure 26. Global Messenger RNA Vaccines and Therapeutics Consumption Value Share by Type (2018-2023)
Figure 27. Global Messenger RNA Vaccines and Therapeutics Market Share Forecast by Type (2024-2029)
Figure 28. Global Messenger RNA Vaccines and Therapeutics Consumption Value Share by Application (2018-2023)
Figure 29. Global Messenger RNA Vaccines and Therapeutics Market Share Forecast by Application (2024-2029)
Figure 30. North America Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 31. North America Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 32. North America Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 33. United States Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 34. Canada Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 35. Mexico Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 36. Europe Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 37. Europe Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 38. Europe Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 39. Germany Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 40. France Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 41. United Kingdom Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 42. Russia Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 43. Italy Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 44. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 45. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 46. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 47. China Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 48. Japan Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 49. South Korea Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 50. India Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 51. Southeast Asia Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 52. Australia Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 53. South America Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 54. South America Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 55. South America Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 56. Brazil Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 57. Argentina Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 58. Middle East and Africa Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 59. Middle East and Africa Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 60. Middle East and Africa Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 61. Turkey Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 62. Saudi Arabia Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 63. UAE Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 64. Messenger RNA Vaccines and Therapeutics Market Drivers
Figure 65. Messenger RNA Vaccines and Therapeutics Market Restraints
Figure 66. Messenger RNA Vaccines and Therapeutics Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Manufacturing Cost Structure Analysis of Messenger RNA Vaccines and Therapeutics in 2022
Figure 69. Manufacturing Process Analysis of Messenger RNA Vaccines and Therapeutics
Figure 70. Messenger RNA Vaccines and Therapeutics Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
Figure 1. Messenger RNA Vaccines and Therapeutics Picture
Figure 2. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type in 2022
Figure 4. Self-amplifying
Figure 5. Conventional Non-amplifying
Figure 6. Global Messenger RNA Vaccines and Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application in 2022
Figure 8. Cancer Picture
Figure 9. Infectious Diseases Picture
Figure 10. Autoimmune Diseases Picture
Figure 11. Others Picture
Figure 12. Global Messenger RNA Vaccines and Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Messenger RNA Vaccines and Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Market Messenger RNA Vaccines and Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 15. Global Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 16. Global Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Region in 2022
Figure 17. North America Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. Europe Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. South America Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. Middle East and Africa Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. Global Messenger RNA Vaccines and Therapeutics Revenue Share by Players in 2022
Figure 23. Messenger RNA Vaccines and Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 24. Global Top 3 Players Messenger RNA Vaccines and Therapeutics Market Share in 2022
Figure 25. Global Top 6 Players Messenger RNA Vaccines and Therapeutics Market Share in 2022
Figure 26. Global Messenger RNA Vaccines and Therapeutics Consumption Value Share by Type (2018-2023)
Figure 27. Global Messenger RNA Vaccines and Therapeutics Market Share Forecast by Type (2024-2029)
Figure 28. Global Messenger RNA Vaccines and Therapeutics Consumption Value Share by Application (2018-2023)
Figure 29. Global Messenger RNA Vaccines and Therapeutics Market Share Forecast by Application (2024-2029)
Figure 30. North America Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 31. North America Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 32. North America Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 33. United States Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 34. Canada Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 35. Mexico Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 36. Europe Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 37. Europe Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 38. Europe Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 39. Germany Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 40. France Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 41. United Kingdom Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 42. Russia Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 43. Italy Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 44. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 45. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 46. Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 47. China Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 48. Japan Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 49. South Korea Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 50. India Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 51. Southeast Asia Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 52. Australia Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 53. South America Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 54. South America Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 55. South America Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 56. Brazil Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 57. Argentina Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 58. Middle East and Africa Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 59. Middle East and Africa Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 60. Middle East and Africa Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 61. Turkey Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 62. Saudi Arabia Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 63. UAE Messenger RNA Vaccines and Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 64. Messenger RNA Vaccines and Therapeutics Market Drivers
Figure 65. Messenger RNA Vaccines and Therapeutics Market Restraints
Figure 66. Messenger RNA Vaccines and Therapeutics Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Manufacturing Cost Structure Analysis of Messenger RNA Vaccines and Therapeutics in 2022
Figure 69. Manufacturing Process Analysis of Messenger RNA Vaccines and Therapeutics
Figure 70. Messenger RNA Vaccines and Therapeutics Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
